Patents by Inventor Boopathy Ramakrishnan

Boopathy Ramakrishnan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized complement 5a receptor 1 antibodies and methods of use thereof
    Patent number: 12264203
    Abstract: The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.
    Type: Grant
    Filed: May 31, 2024
    Date of Patent: April 1, 2025
    Assignee: Visterra, Inc.
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver, Lauren Olinski
  • NUCLEIC ACID MOLECULES ENCODING ANTIBODIES TO A PROLIFERATION-INDUCING LIGAND (APRIL)
    Publication number: 20250066464
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Application
    Filed: July 31, 2024
    Publication date: February 27, 2025
    Applicant: VISTERRA, INC.
    Inventors: James R. MYETTE, Zachary Holmes SHRIVER, Karthik VISWANATHAN, Andrew M. WOLLACOTT, Hedy ADARI-HALL, Boopathy RAMAKRISHNAN, Gregory BABCOCK
  • INTERLEUKIN-2 AGENTS AND USES THEREOF
    Publication number: 20250059249
    Abstract: IL-2 agents that comprise IL-2 variants are disclosed as well as methods, compositions, and uses thereof. The IL-2 agents described herein can be used to treat and/or prevent various disorders and conditions.
    Type: Application
    Filed: October 31, 2024
    Publication date: February 20, 2025
    Inventors: Scott Moore Carlson, Gregory Babcock, Zachary Shriver, Boopathy Ramakrishnan
  • Humanized complement 5A receptor 1 antibodies and methods of use thereof
    Patent number: 12227587
    Abstract: The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.
    Type: Grant
    Filed: January 17, 2024
    Date of Patent: February 18, 2025
    Assignee: Visterra, Inc.
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver, Lauren Olinski
  • ANTIBODY MOLECULES TO APRIL AND USES THEREOF
    Publication number: 20250043014
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Application
    Filed: August 23, 2024
    Publication date: February 6, 2025
    Applicant: VISTERRA, INC.
    Inventors: David William OLDACH, James R. MYETTE, Zachary SHRIVER, Karthik VISWANATHAN, Andrew M. WOLLACOTT, Hedy ADARI-HALL, Boopathy RAMAKRISHNAN, Gregory BABCOCK, Jill YARBROUGH, Asher SCHACHTER, Mohit MATHUR
  • Antibody molecules to C5AR1 and uses thereof
    Patent number: 12187807
    Abstract: Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.
    Type: Grant
    Filed: August 18, 2023
    Date of Patent: January 7, 2025
    Assignee: Visterra, Inc.
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver
  • HUMANIZED COMPLEMENT 5A RECEPTOR 1 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20250002603
    Abstract: The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.
    Type: Application
    Filed: January 17, 2024
    Publication date: January 2, 2025
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver, Lauren Olinski
  • HUMANIZED COMPLEMENT 5A RECEPTOR 1 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20240392029
    Abstract: The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.
    Type: Application
    Filed: May 31, 2024
    Publication date: November 28, 2024
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver, Lauren Olinski
  • METHODS OF USING INTERLEUKIN-2 AGENTS
    Publication number: 20240376173
    Abstract: IL-2 agents that comprise IL-2 variants are disclosed as well as methods, compositions, and uses thereof. The IL-2 agents described herein can be used to treat and/or prevent various disorders and conditions.
    Type: Application
    Filed: July 26, 2024
    Publication date: November 14, 2024
    Inventors: Scott Moore Carlson, Gregory Babcock, Zachary Shriver, Boopathy Ramakrishnan, Thiago de Jesus Borges, Leonardo Vidal Riella
  • ANTIBODY MOLECULE-DRUG CONJUGATES AND USES THEREOF
    Publication number: 20240342300
    Abstract: Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.
    Type: Application
    Filed: February 7, 2024
    Publication date: October 17, 2024
    Inventors: Karthik Viswanathan, Kenneth Douglas Johnson, Obadiah Joseph Plante, James C. Delaney, Tyree J. Koch, Hamid Tissire, Andrew M. Wollacott, Boopathy Ramakrishnan
  • Methods of using interleukin-2 agents
    Patent number: 12098178
    Abstract: IL-2 agents that comprise IL-2 variants are disclosed as well as methods, compositions, and uses thereof. The IL-2 agents described herein can be used to treat and/or prevent various disorders and conditions.
    Type: Grant
    Filed: December 3, 2021
    Date of Patent: September 24, 2024
    Assignees: Visterra, Inc., The General Hospital Corporation
    Inventors: Scott Moore Carlson, Gregory Babcock, Zachary Shriver, Boopathy Ramakrishnan, Thiago de Jesus Borges, Leonardo Vidal Riella
  • Method of using antibody molecules to detect a proliferation-inducing ligand (APRIL)
    Patent number: 12091451
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: September 17, 2024
    Assignee: VISTERRA, INC.
    Inventors: James R. Myette, Zachary Holmes Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock
  • ANTIBODY MOLECULES TO CD138 AND USES THEREOF
    Publication number: 20240301065
    Abstract: Antibody molecules that specifically bind to CD138 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as multiple myeloma.
    Type: Application
    Filed: February 20, 2024
    Publication date: September 12, 2024
    Inventors: Bharat Chaganty, Boopathy Ramakrishnan, Hedy Adari-Hall, Karthik Viswanathan, James R. Myette, Zachary Shriver
  • Interleukin-2 agents and uses thereof
    Patent number: 12084484
    Abstract: IL-2 agents that comprise IL-2 variants are disclosed as well as methods, compositions, and uses thereof. The IL-2 agents described herein can be used to treat and/or prevent various disorders and conditions.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: September 10, 2024
    Assignee: Visterra, Inc.
    Inventors: Scott Moore Carlson, Gregory Babcock, Zachary Shriver, Boopathy Ramakrishnan
  • INTERLEUKIN-2 AGENTS AND USES THEREOF
    Publication number: 20240247040
    Abstract: IL-2 agents that comprise IL-2 variants are disclosed as well as methods, compositions, and uses thereof. The IL-2 agents described herein can be used to treat and/or prevent various disorders and conditions.
    Type: Application
    Filed: March 25, 2024
    Publication date: July 25, 2024
    Inventors: Scott Moore Carlson, Gregory Babcock, Zachary Shriver, Boopathy Ramakrishnan
  • Antibody Molecules to C5AR1 and Uses Thereof
    Publication number: 20240150488
    Abstract: Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.
    Type: Application
    Filed: September 29, 2023
    Publication date: May 9, 2024
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver
  • Antibody molecule-drug conjugates and uses thereof
    Patent number: 11969476
    Abstract: Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: April 30, 2024
    Assignee: VISTERRA, INC.
    Inventors: Karthik Viswanathan, Kenneth Douglas Johnson, Obadiah Joseph Plante, James C. Delaney, Tyree J. Koch, Hamid Tissire, Andrew M. Wollacott, Boopathy Ramakrishnan
  • Antibody molecules to CD138 and uses thereof
    Patent number: 11945868
    Abstract: Antibody molecules that specifically bind to CD138 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as multiple myeloma.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: April 2, 2024
    Assignee: VISTERRA, INC.
    Inventors: Bharat Chaganty, Boopathy Ramakrishnan, Hedy Adari-Hall, Karthik Viswanathan, James R. Myette, Zachary Shriver
  • ANTIBODY MOLECULES TO APRIL AND USES THEREOF
    Publication number: 20240092921
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Application
    Filed: April 24, 2023
    Publication date: March 21, 2024
    Inventors: David William Oldach, James R. Myette, Zachary Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock, Jill Yarbrough, Asher Schachter, Mohit Mathur
  • Antibody Molecules to C5AR1 and Uses Thereof
    Publication number: 20240076398
    Abstract: Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.
    Type: Application
    Filed: August 18, 2023
    Publication date: March 7, 2024
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver